HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
STVN
Stevanato Group S.p.A.
STVN's fundamentals are mixed: revenue grew 6.7%, but earnings per share fell 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
STVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
STVN's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
STVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 27x | $14.36 | — |
| Cheap | 31x | $16.55 | +15% |
| Fair | 39x | $20.56 | +43% |
| Expensive | 49x | $25.80 | +80% |
Historical ranges are pointers, not guarantees.
STVN's PE is 27x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
STVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect STVN's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
STVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.53 | -5.4% |
| Q1 2026 | $0.57 | +9.6% |
| Q4 2025 | $0.57 | +16% |
| Q3 2025 | $0.58 | +23% |
| Q2 2025 | $0.56 | +7.7% |
| Q1 2025 | $0.52 | -10% |
| Q4 2024 | $0.49 | -21% |
| Q3 2024 | $0.47 | -24% |
STVN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over STVN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
STVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $335.5M | +7.8% |
| Q1 2026 | $303.9M | +6.6% |
| Q4 2025 | $381.3M | +3.8% |
| Q3 2025 | $336.8M | +9.1% |
| Q2 2025 | $311.1M | +7.9% |
| Q1 2025 | $285.1M | +8.7% |
| Q4 2024 | $367.3M | +3.1% |
| Q3 2024 | $308.7M | +2.4% |
STVN's revenue has grown year over year for nine quarters in a row: $335M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -1.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 19% | -1 points |
| Q3 2025 | 17% | +2.6 points |
| Q2 2025 | 15% | +4 points |
| Q1 2025 | 14% | +2.8 points |
| Q4 2024 | 20% | +0.3 points |
| Q3 2024 | 15% | -4.1 points |
STVN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over STVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
STVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$37.6M | -$20.6M |
| Q1 2026 | $5.3M | -83% |
| Q4 2025 | $5.2M | +$55.4M |
| Q3 2025 | -$1.3M | +$121.2M |
| Q2 2025 | -$17.1M | +$34.6M |
| Q1 2025 | $31.2M | +$65.7M |
| Q4 2024 | -$50.3M | +$35.2M |
| Q3 2024 | -$122.5M | +$166.1M |
STVN has burned cash in most quarters: −$28M over the past year, against −$159M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over STVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
STVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -21.1K shares |
| 1 year | 0% | +77K shares |
| 3 years | +2.9% | +7.6M shares |
| 5 years | -9.1% | -27.4M shares |
| Available history | -7.4% | -21.8M shares |
STVN has 273M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
STVN hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over STVN on leverage, with a lower net debt burden relative to earnings.
STVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.0x | Healthy |
| Q1 2025 | 1.0x | Healthy |
| Q4 2024 | 1.1x | Healthy |
| Q3 2024 | 1.0x | Healthy |
STVN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
STVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 17.5 | Oversold |
STVN's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
STVN PE vs Healthcare Sector
| Metric | STVN | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 4.2% above |
| PE % | 6 | 38 | 32 pts below |
STVN is trading at 27x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
STVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.3 | 22% below |
| 20 week MA | $19.6 | 27% below |
| 50 week MA | $18.2 | 21% below |
| 100 week MA | $20.7 | 30% below |
| 200 week MA | $23.1 | 38% below |
STVN is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
STVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.7 | $23.3 | +19% |
| 2022 | $23.3 | $17.9 | -23% |
| 2023 | $17.9 | $27.3 | +53% |
| 2024 | $27.3 | $21.6 | -21% |
| 2025 | $21.6 | $20.7 | -4.2% |
| 2026 YTD | $20.7 | $14.4 | -31% |
STVN has the edge over HIMS on returns for 2026, with the stronger performance.